CA2642274A1 - Receptacle for the separation of tumor cells - Google Patents
Receptacle for the separation of tumor cells Download PDFInfo
- Publication number
- CA2642274A1 CA2642274A1 CA002642274A CA2642274A CA2642274A1 CA 2642274 A1 CA2642274 A1 CA 2642274A1 CA 002642274 A CA002642274 A CA 002642274A CA 2642274 A CA2642274 A CA 2642274A CA 2642274 A1 CA2642274 A1 CA 2642274A1
- Authority
- CA
- Canada
- Prior art keywords
- container
- tumour cells
- compartment
- biological sample
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000004881 tumor cell Anatomy 0.000 title claims abstract description 109
- 238000000926 separation method Methods 0.000 title claims description 67
- 239000000126 substance Substances 0.000 claims abstract description 71
- 230000009974 thixotropic effect Effects 0.000 claims abstract description 58
- 239000012472 biological sample Substances 0.000 claims abstract description 54
- 238000000034 method Methods 0.000 claims description 57
- 210000004027 cell Anatomy 0.000 claims description 54
- 230000004888 barrier function Effects 0.000 claims description 45
- 206010028980 Neoplasm Diseases 0.000 claims description 37
- 238000005119 centrifugation Methods 0.000 claims description 36
- 239000008280 blood Substances 0.000 claims description 32
- 210000004369 blood Anatomy 0.000 claims description 29
- 239000000523 sample Substances 0.000 claims description 27
- 238000012360 testing method Methods 0.000 claims description 27
- 238000004220 aggregation Methods 0.000 claims description 16
- 230000002776 aggregation Effects 0.000 claims description 15
- 230000002401 inhibitory effect Effects 0.000 claims description 15
- 230000001413 cellular effect Effects 0.000 claims description 13
- 210000001124 body fluid Anatomy 0.000 claims description 12
- 239000010839 body fluid Substances 0.000 claims description 12
- 239000012530 fluid Substances 0.000 claims description 12
- 210000001772 blood platelet Anatomy 0.000 claims description 11
- 238000003752 polymerase chain reaction Methods 0.000 claims description 9
- 210000001519 tissue Anatomy 0.000 claims description 8
- 210000003743 erythrocyte Anatomy 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 238000010240 RT-PCR analysis Methods 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 230000015271 coagulation Effects 0.000 claims description 6
- 238000005345 coagulation Methods 0.000 claims description 6
- 229920001971 elastomer Polymers 0.000 claims description 6
- 210000000416 exudates and transudate Anatomy 0.000 claims description 6
- 230000002209 hydrophobic effect Effects 0.000 claims description 6
- 201000005296 lung carcinoma Diseases 0.000 claims description 6
- 210000004698 lymphocyte Anatomy 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 229920001917 Ficoll Polymers 0.000 claims description 5
- 210000001185 bone marrow Anatomy 0.000 claims description 5
- 239000000806 elastomer Substances 0.000 claims description 5
- 230000001900 immune effect Effects 0.000 claims description 5
- 210000000265 leukocyte Anatomy 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 210000001616 monocyte Anatomy 0.000 claims description 5
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 239000000975 dye Substances 0.000 claims description 4
- 210000002751 lymph Anatomy 0.000 claims description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 3
- 239000005995 Aluminium silicate Substances 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 3
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 3
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- -1 Percoll® Chemical class 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 229940072056 alginate Drugs 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 235000012211 aluminium silicate Nutrition 0.000 claims description 3
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000000440 bentonite Substances 0.000 claims description 3
- 229910000278 bentonite Inorganic materials 0.000 claims description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 3
- 238000004113 cell culture Methods 0.000 claims description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 229960005423 diatrizoate Drugs 0.000 claims description 3
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 claims description 3
- 229910000271 hectorite Inorganic materials 0.000 claims description 3
- 230000002489 hematologic effect Effects 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 238000009396 hybridization Methods 0.000 claims description 3
- 238000011065 in-situ storage Methods 0.000 claims description 3
- 201000002313 intestinal cancer Diseases 0.000 claims description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 208000017830 lymphoblastoma Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 239000011148 porous material Substances 0.000 claims description 3
- 201000001514 prostate carcinoma Diseases 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 208000020615 rectal carcinoma Diseases 0.000 claims description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 210000000582 semen Anatomy 0.000 claims description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims description 3
- 235000012239 silicon dioxide Nutrition 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 208000001608 teratocarcinoma Diseases 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 239000011534 wash buffer Substances 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 claims 1
- 230000002744 anti-aggregatory effect Effects 0.000 claims 1
- 230000002429 anti-coagulating effect Effects 0.000 claims 1
- 230000008901 benefit Effects 0.000 description 8
- 210000000601 blood cell Anatomy 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 230000008569 process Effects 0.000 description 7
- 239000000872 buffer Substances 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 238000001816 cooling Methods 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 108091092328 cellular RNA Proteins 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000005266 circulating tumour cell Anatomy 0.000 description 2
- 230000002380 cytological effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000000779 depleting effect Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000007898 magnetic cell sorting Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000009391 cell specific gene expression Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000001821 nucleic acid purification Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
- C12N5/0093—Purging against cancer cells
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5021—Test tubes specially adapted for centrifugation purposes
- B01L3/50215—Test tubes specially adapted for centrifugation purposes using a float to separate phases
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/04—Closures and closing means
- B01L2300/041—Connecting closures to device or container
- B01L2300/044—Connecting closures to device or container pierceable, e.g. films, membranes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0681—Filter
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/069—Absorbents; Gels to retain a fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Clinical Laboratory Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Sampling And Sample Adjustment (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05003640A EP1693109A1 (de) | 2005-02-21 | 2005-02-21 | Behältnis zur Separation von Tumorzellen |
| EP05003640.9 | 2005-02-21 | ||
| PCT/EP2006/001496 WO2006087220A2 (de) | 2005-02-21 | 2006-02-20 | Behältnis zur separation von tumorzellen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2642274A1 true CA2642274A1 (en) | 2006-08-24 |
Family
ID=34933847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002642274A Abandoned CA2642274A1 (en) | 2005-02-21 | 2006-02-20 | Receptacle for the separation of tumor cells |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090186341A1 (enExample) |
| EP (1) | EP1693109A1 (enExample) |
| JP (1) | JP2008529541A (enExample) |
| AU (1) | AU2006215776A1 (enExample) |
| CA (1) | CA2642274A1 (enExample) |
| WO (1) | WO2006087220A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008022651A1 (en) | 2006-08-21 | 2008-02-28 | Antoine Turzi | Process and device for the preparation of platelet rich plasma for extemporaneous use and combination thereof with skin and bone cells |
| EP2067855A1 (de) | 2007-12-07 | 2009-06-10 | Michael W. Dahm | Anreicherung und Nachweis von fetalen Zellen aus maternalem Blut |
| ES2390171T3 (es) | 2008-07-21 | 2012-11-07 | Becton, Dickinson And Company | Dispositivo de separación de fases de densidad |
| JP5607621B2 (ja) | 2008-07-21 | 2014-10-15 | ベクトン・ディキンソン・アンド・カンパニー | 密度相分離デバイス |
| CN104588140B (zh) | 2008-07-21 | 2016-06-29 | 贝克顿·迪金森公司 | 密度相分离装置 |
| EP2918344B1 (en) | 2009-05-15 | 2021-06-30 | Becton, Dickinson and Company | Density phase separation device |
| WO2011069145A2 (en) * | 2009-12-04 | 2011-06-09 | Becton, Dickinson And Company | Blood collection tube with separation barrier |
| EP2500095A1 (de) * | 2011-03-15 | 2012-09-19 | Siemens Healthcare Diagnostics Products GmbH | Vorrichtungen und Verfahren zur Bestimmung der Plättchenfunktion in einem Zentrifugalanalyzer |
| EP2848935A4 (en) | 2012-05-10 | 2015-12-09 | Konica Minolta Inc | PROCESS FOR REMOVING RED BLOOD BODIES AND CENTRIFUGAL TUBES FOR BLOOD TREATMENT |
| EP2810717B1 (en) * | 2013-06-06 | 2018-10-17 | F. Hoffmann-La Roche AG | Acceleration sensitive indicator |
| WO2014202957A1 (en) | 2013-06-19 | 2014-12-24 | Brightwake Limited | Cell collecting device |
| US9694359B2 (en) | 2014-11-13 | 2017-07-04 | Becton, Dickinson And Company | Mechanical separator for a biological fluid |
| CN105368706A (zh) * | 2015-12-11 | 2016-03-02 | 何守贵 | 大容量单个核细胞分离瓶 |
| JP6779483B2 (ja) | 2016-09-29 | 2020-11-04 | 住友ゴム工業株式会社 | 医療用検査装置及び細胞検査方法 |
| JP2018157812A (ja) * | 2017-03-23 | 2018-10-11 | 東ソー株式会社 | 試料中に含まれる細胞の検出方法 |
| US20210146352A1 (en) * | 2017-07-24 | 2021-05-20 | Epitope Diagnostics, Inc. | Fecal sample collection and analyte extraction device and method |
| JP7109719B2 (ja) | 2018-02-14 | 2022-08-01 | 住友ゴム工業株式会社 | 特定細胞捕捉方法 |
| JP7170254B2 (ja) * | 2018-02-14 | 2022-11-14 | 住友ゴム工業株式会社 | 特定細胞捕捉方法 |
| US11614440B2 (en) * | 2019-01-24 | 2023-03-28 | Sumitomo Rubber Industries, Ltd. | Specific cell fractionating and capturing methods |
| KR20240005874A (ko) * | 2021-05-05 | 2024-01-12 | 살루스 디스커버리 엘엘씨 | 안정적인 계면 시스템 및 조성물 |
| CN114832471A (zh) * | 2022-05-20 | 2022-08-02 | 深圳华大医学检验实验室 | 一种滤芯及其过滤装置与方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4844818A (en) * | 1987-10-23 | 1989-07-04 | Becton Dickinson & Company | Method for separating the cellular components of blood samples |
| US4867887A (en) * | 1988-07-12 | 1989-09-19 | Becton Dickinson And Company | Method and apparatus for separating mononuclear cells from blood |
| US5494590A (en) * | 1992-06-11 | 1996-02-27 | Becton Dickinson | Method of using anticoagulant solution in blood separation |
| US5840502A (en) * | 1994-08-31 | 1998-11-24 | Activated Cell Therapy, Inc. | Methods for enriching specific cell-types by density gradient centrifugation |
| CA2239729C (en) * | 1995-12-11 | 2006-10-31 | Dendreon Corporation | Cell separation composition, kit and method |
| DE19904267A1 (de) * | 1999-02-03 | 2000-08-10 | Michael W Dahm | Verfahren zur Anreicherung von Tumorzellen aus einer Körperflüssigkeit und dazu geeigneter Kit |
| DE50309796D1 (de) * | 2002-08-14 | 2008-06-19 | Hexal Gentech Forschungsgmbh | Verfahren zum immunzytologischen oder molekularen nachweis von disseminierten tumorzellen aus einer körperflüssigkeit und dazu geeigneter kit |
-
2005
- 2005-02-21 EP EP05003640A patent/EP1693109A1/de not_active Withdrawn
-
2006
- 2006-02-20 US US11/816,742 patent/US20090186341A1/en not_active Abandoned
- 2006-02-20 JP JP2007555539A patent/JP2008529541A/ja active Pending
- 2006-02-20 CA CA002642274A patent/CA2642274A1/en not_active Abandoned
- 2006-02-20 WO PCT/EP2006/001496 patent/WO2006087220A2/de not_active Ceased
- 2006-02-20 AU AU2006215776A patent/AU2006215776A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20090186341A1 (en) | 2009-07-23 |
| WO2006087220A2 (de) | 2006-08-24 |
| AU2006215776A1 (en) | 2006-08-24 |
| EP1693109A1 (de) | 2006-08-23 |
| WO2006087220A3 (de) | 2006-10-12 |
| JP2008529541A (ja) | 2008-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090186341A1 (en) | Receptacle for the Separation of Tumor Cells | |
| Hyun et al. | Isolation and enrichment of circulating biomarkers for cancer screening, detection, and diagnostics | |
| DK2542689T3 (en) | Method for isolating target cells | |
| US9095798B2 (en) | Centrifuge separation method and apparatus using a medium density fluid | |
| US9101925B2 (en) | Centrifuge and separation vessel therefore | |
| CN105954246B (zh) | 一种在人的生物液体样本中检测游离的稀有肿瘤细胞的方法和试剂盒 | |
| Au et al. | Clusters of circulating tumor cells: a biophysical and technological perspective | |
| JP2002536635A (ja) | 体液から腫瘍細胞を濃縮するか又は除去する方法及びかかる目的に適したキット | |
| WO2006050352A1 (en) | Blood test prototypes and methods for the detetion of circulating tumor and endothelial cells | |
| US20160167061A1 (en) | Method and system for buoyant separation | |
| KR20160019475A (ko) | 체액으로부터의 산발성 세포를 분리하는 방법 및 상기 방법을 수행하기 위한 장치 | |
| JP2023508411A (ja) | 血液試料からセルフリー核酸を抽出するための方法、自動化システムおよびカートリッジ | |
| CN111812323B (zh) | 己糖激酶2用于体液样本中稀有肿瘤细胞检测及试剂盒 | |
| JP6617516B2 (ja) | 血液試料中に含まれる目的細胞の検出方法 | |
| CN111751543A (zh) | 一种稀有肿瘤细胞富集方法及试剂盒 | |
| CN107208164A (zh) | 用于对循环肿瘤细胞进行测序的血液样品处理 | |
| CN106281962A (zh) | 基于靶向多肽的循环肿瘤细胞捕获方法及微流芯片 | |
| CN108220233A (zh) | 细胞分离器具表面处理方法、相关器具、外周血稀有细胞或循环肿瘤细胞快速高效分离方法 | |
| AU2016395556B2 (en) | Method for detecting or separating/obtaining circulating tumor cell employing cell proliferation method | |
| CN114096849A (zh) | 使用了病毒的循环肿瘤细胞的检测方法 | |
| JP7279542B2 (ja) | 試料中に含まれる目的細胞の定量方法 | |
| JP2018157812A (ja) | 試料中に含まれる細胞の検出方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |